Literature DB >> 29214872

Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Christopher Crockford1,2, Judith Newton1,3, Katie Lonergan4,5, Caoifa Madden4,5, Iain Mays4,5, Meabhdh O'Sullivan4, Emmet Costello4,5, Marta Pinto-Grau4,5, Alice Vajda4, Mark Heverin4, Niall Pender5, Ammar Al-Chalabi6, Orla Hardiman4,7, Sharon Abrahams1,2,3.   

Abstract

BACKGROUND: Cognitive impairment affects approximately 50% of people with amyotrophic lateral sclerosis (ALS). Research has indicated that impairment may worsen with disease progression. The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was designed to measure neuropsychological functioning in ALS, with its alternate forms (ECAS-A, B, and C) allowing for serial assessment over time.
OBJECTIVE: The aim of the present study was to establish reliable change scores for the alternate forms of the ECAS, and to explore practice effects and test-retest reliability of the ECAS's alternate forms.
METHOD: Eighty healthy participants were recruited, with 57 completing two and 51 completing three assessments. Participants were administered alternate versions of the ECAS serially (A-B-C) at four-month intervals. Intra-class correlation analysis was employed to explore test-retest reliability, while analysis of variance was used to examine the presence of practice effects. Reliable change indices (RCI) and regression-based methods were utilized to establish change scores for the ECAS alternate forms.
RESULTS: Test-retest reliability was excellent for ALS Specific, ALS Non-Specific, and ECAS Total scores of the combined ECAS A, B, and C (all > .90). No significant practice effects were observed over the three testing sessions. RCI and regression-based methods produced similar change scores.
CONCLUSION: The alternate forms of the ECAS possess excellent test-retest reliability in a healthy control sample, with no significant practice effects. The use of conservative RCI scores is recommended. Therefore, a change of ≥8, ≥4, and ≥9 for ALS Specific, ALS Non-Specific, and ECAS Total score is required for reliable change.

Entities:  

Keywords:  Cognition; ECAS; alternate forms; practice; test reliability

Mesh:

Year:  2017        PMID: 29214872      PMCID: PMC6510059          DOI: 10.1080/21678421.2017.1407794

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  26 in total

1.  Detecting significant change in neuropsychological test performance: a comparison of four models.

Authors:  N R Temkin; R K Heaton; I Grant; S S Dikmen
Journal:  J Int Neuropsychol Soc       Date:  1999-05       Impact factor: 2.892

2.  Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.

Authors:  N S Jacobson; P Truax
Journal:  J Consult Clin Psychol       Date:  1991-02

Review 3.  Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM.

Authors:  Joseph P Weir
Journal:  J Strength Cond Res       Date:  2005-02       Impact factor: 3.775

4.  The effects of executive and behavioral dysfunction on the course of ALS.

Authors:  R K Olney; J Murphy; D Forshew; E Garwood; B L Miller; S Langmore; M A Kohn; C Lomen-Hoerth
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

5.  Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS).

Authors:  S Abrahams; P N Leigh; A Harvey; G N Vythelingum; D Grisé; L H Goldstein
Journal:  Neuropsychologia       Date:  2000       Impact factor: 3.139

Review 6.  The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly - a systematic review.

Authors:  Janine Stein; Melanie Luppa; Elmar Brähler; Hans-Helmut König; Steffi G Riedel-Heller
Journal:  Dement Geriatr Cogn Disord       Date:  2010-04-07       Impact factor: 2.959

7.  The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study.

Authors:  I C Newsom-Davis; R A Lyall; P N Leigh; J Moxham; L H Goldstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

8.  Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.

Authors:  M Elamin; J Phukan; P Bede; N Jordan; S Byrne; N Pender; O Hardiman
Journal:  Neurology       Date:  2011-04-05       Impact factor: 9.910

9.  Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life.

Authors:  A Chiò; A Vignola; E Mastro; A Dei Giudici; B Iazzolino; A Calvo; C Moglia; A Montuschi
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

10.  Comparing patients' predicted test scores from a regression equation with their obtained scores: a significance test and point estimate of abnormality with accompanying confidence limits.

Authors:  John R Crawford; Paul H Garthwaite
Journal:  Neuropsychology       Date:  2006-05       Impact factor: 3.295

View more
  7 in total

1.  ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability.

Authors:  Lucio Tremolizzo; Andrea Lizio; Gabriella Santangelo; Susanna Diamanti; Christian Lunetta; Francesca Gerardi; Sonia Messina; Stefania La Foresta; Nilo Riva; Yuri Falzone; Massimo Filippi; Susan C Woolley; Valeria Ada Sansone; Mattia Siciliano; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Neurol Sci       Date:  2019-12-05       Impact factor: 3.307

2.  Assessing and validating reliable change across ADNI protocols.

Authors:  Dustin B Hammers; Ralitsa Kostadinova; Frederick W Unverzagt; Liana G Apostolova
Journal:  J Clin Exp Neuropsychol       Date:  2022-07-04       Impact factor: 2.283

3.  Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.

Authors:  Corey T McMillan; Joanne Wuu; Katya Rascovsky; Stephanie Cosentino; Murray Grossman; Lauren Elman; Colin Quinn; Luis Rosario; Jessica H Stark; Volkan Granit; Hannah Briemberg; Sneha Chenji; Annie Dionne; Angela Genge; Wendy Johnston; Lawrence Korngut; Christen Shoesmith; Lorne Zinman; Sanjay Kalra; Michael Benatar
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2022-03-07       Impact factor: 3.528

4.  Validation of one-week reliable change methods in cognitively intact community-dwelling older adults.

Authors:  Dustin B Hammers; Kayla R Suhrie; Ava Dixon; Sariah Porter; Kevin Duff
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2020-07-02

Review 5.  Palliative care in motor neurone disease: where are we now?

Authors:  David J Oliver
Journal:  Palliat Care       Date:  2019-01-21

Review 6.  Qualitative measures that assess functional disability and quality of life in ALS.

Authors:  Susan L Hartmaier; Thomas Rhodes; Suzanne F Cook; Courtney Schlusser; Chao Chen; Steve Han; Neta Zach; Venkatesha Murthy; Shreya Davé
Journal:  Health Qual Life Outcomes       Date:  2022-01-21       Impact factor: 3.186

7.  A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.

Authors:  Emily Beswick; Deborah Forbes; Zack Hassan; Charis Wong; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2021-06-13       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.